Suzetrigine as a novel treatment for headache disorders: A case series

Authors

• Molly Fensterwald, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Jordan Johnson, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Angel Moreno, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Shawn Conger-Love, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Charles Flippen, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Chelsea Hesterman, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Mollie Johnston, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Joshua Kamins, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Karla Minota, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Peony Pak, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Salman Hashim, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Thanh-Liem Huynh-Tran, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Noelle Kobayashi, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Bradley Shane, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Andrew Charles, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
• Sinifunanya Nwaobi, Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.

Document Type

Article

Abstract

Suzetrigine is a selective voltage-gated sodium channel blocker that was recently approved by the US Food and Drug Administration for the treatment of acute pain. We retrospectively evaluated the efficacy and tolerability of suzetrigine for the treatment of different headache disorders in patients refractory to standard treatments in an academic headache center. These patients had a variety of headache and facial pain diagnoses, including chronic migraine, medication-overuse headache, trigeminal autonomic cephalalgias, nummular headache, occipital neuralgia, and persistent idiopathic facial pain. Some did not clearly meet any diagnostic criteria. The treatment was generally well tolerated, and most patients reported improvement as measured by patient global impression of change. Suzetrigine is a promising new therapeutic approach that warrants further study for the treatment of headache disorders.

Medical Subject Headings

Humans; Female; Headache Disorders (drug therapy); Male; Middle Aged; Adult; Retrospective Studies; Treatment Outcome; Aged; Amides; Aminopyridines; Furans

Publication Date

1-1-2026

Publication Title

Headache

E-ISSN

1526-4610

Volume

66

Issue

7

First Page

1644

Last Page

1649

PubMed ID

42249666

Digital Object Identifier (DOI)

10.1111/head.70147

Recommended Citation

Fensterwald, Molly; Johnson, Jordan; Moreno, Angel; Conger-Love, Shawn; Flippen, Charles; Hesterman, Chelsea; Johnston, Mollie; Kamins, Joshua; Minota, Karla; Pak, Peony; Hashim, Salman; Huynh-Tran, Thanh-Liem; Kobayashi, Noelle; Shane, Bradley; Charles, Andrew; and Nwaobi, Sinifunanya, "Suzetrigine as a novel treatment for headache disorders: A case series" (2026). Neurology. 2101.
https://scholar.barrowneuro.org/neurology/2101